Table III.
Univariate analysis of DFS- and OS-associated factors.
| P-value (log-rank test) | ||||
|---|---|---|---|---|
| Variable | DFS | OS | ||
| Age (years) | ≤60 (n=15) | >60 (N=24) | 0.33 | 0.11 |
| Sex | Male (n=24) | Female (N=15) | 0.36 | 0.018 |
| T-stage | T3,T4 (n=9) | T1,T2 (N=30) | 0.64 | 0.69 |
| Histology | Sq (n=4) | Non-Sq (N=35) | 0.63 | 0.054 |
| EGFR status | Mutant (n=18) | Wild-type (N=17) | 0.065 | 0.95 |
| Regimen (CD-DST) | Non-sensitive (n=14) | Sensitive (n=25) | 0.037 | 0.76 |
| Regimen (CDDP/CBDCA) | CDDP-based (n=34) | CBDCA-based (n=5) | 0.81 | 0.56 |
| Chemotherapy completeness | No (n=6) | Yes (n=33) | 0.55 | 0.14 |
DFS, disease-free survival; OS, overall survival; T (stage), tumor; EGFR, epidermal growth factor receptor; CD-DST, collagen gel droplet embedded culture drug sensitivity test; CDDP, cisplatin; CBDCA, carboplatin; Sq, squamous; non-Sq, non-squamous.